These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38074343)

  • 1. Telerehabilitation for Lee Silverman Voice Treatment (Tele-LSVT)-Loud on voice intensity and voice use in daily living in people with multiple sclerosis: A protocol for a feasibility and pilot randomized controlled study.
    Vitali C; Fusari G; Baldanzi C; Cacciatore DM; Crispiatico V; Carullo A; Rovaris M; Cattaneo D; Baglio F; Isernia S
    Digit Health; 2023; 9():20552076231218150. PubMed ID: 38074343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
    Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
    J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
    Sackley CM; Rick C; Brady MC; Woolley R; Burton C; Patel S; Masterson-Algar P; Nicoll A; Smith CH; Jowett S; Ives N; Beaton G; Dickson S; Ottridge R; Sharp L; Nankervis H; Clarke CE;
    BMJ; 2024 Jul; 386():e078341. PubMed ID: 38986549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial.
    Crispiatico V; Baldanzi C; Napoletano A; Tomasoni L; Tedeschi F; Groppo E; Rovaris M; Vitali C; Cattaneo D
    Mult Scler; 2022 Jun; 28(7):1081-1090. PubMed ID: 34652243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.
    Scobie S; Jowett S; Lambe T; Patel S; Woolley R; Ives N; Rick C; Smith C; Brady MC; Clarke C; Sackley C
    Pilot Feasibility Stud; 2021 Aug; 7(1):154. PubMed ID: 34372913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study.
    Nozaki S; Fujiu-Kurachi M; Tanimura T; Ishizuka K; Miyata E; Sugishita S; Imai T; Nishiguchi M; Furuta M; Yorifuji S
    Prog Rehabil Med; 2021; 6():20210012. PubMed ID: 33644483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).
    Sackley CM; Smith CH; Rick CE; Brady MC; Ives N; Patel S; Woolley R; Dowling F; Patel R; Roberts H; Jowett S; Wheatley K; Kelly D; Sands G; Clarke CE;
    Pilot Feasibility Stud; 2018; 4():30. PubMed ID: 29344405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversational Vocal Intensity in Parkinson's Disease: Treatment and Environmental Comparisons.
    Konnai R; Van Harn M; Silbergleit A
    J Voice; 2023 Sep; 37(5):707-715. PubMed ID: 34134903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
    Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
    J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
    Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
    Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2023 Mar; 58(2):241-255. PubMed ID: 36036751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
    Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
    Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias.
    Lowit A; Egan A; Hadjivassiliou M
    Cerebellum; 2020 Oct; 19(5):701-714. PubMed ID: 32588316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive Voice Treatment (Lee Silverman Voice Treatment [LSVT LOUD]) for Children With Down Syndrome: Phase I Outcomes.
    Boliek CA; Halpern A; Hernandez K; Fox CM; Ramig L
    J Speech Lang Hear Res; 2022 Apr; 65(4):1228-1262. PubMed ID: 35230877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2022 Jan; 57(1):138-151. PubMed ID: 34767290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
    Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
    J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis.
    Yuan F; Guo X; Wei X; Xie F; Zheng J; Huang Y; Huang Z; Chang Z; Li H; Guo Y; Chen J; Guo J; Tang B; Deng B; Wang Q
    Eur J Neurol; 2020 Oct; 27(10):1957-1970. PubMed ID: 32539227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Lee Silverman Voice Treatment® LOUD on Japanese-Speaking Patients with Parkinson's Disease.
    Nakayama K; Yamamoto T; Oda C; Sato M; Murakami T; Horiguchi S
    Rehabil Res Pract; 2020; 2020():6585264. PubMed ID: 32411475
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT
    Ertan E; Gürvit HI; Hanağası HH; Bilgiç B; Tunçer MA; Yılmaz C
    Logoped Phoniatr Vocol; 2022 Dec; 47(4):262-270. PubMed ID: 34287100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.